0001209191-16-148742.txt : 20161107 0001209191-16-148742.hdr.sgml : 20161107 20161107190855 ACCESSION NUMBER: 0001209191-16-148742 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20161103 FILED AS OF DATE: 20161107 DATE AS OF CHANGE: 20161107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ALBIREO PHARMA, INC. CENTRAL INDEX KEY: 0001322505 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 MILK STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 BUSINESS PHONE: 857-415-4774 MAIL ADDRESS: STREET 1: 50 MILK STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 FORMER COMPANY: FORMER CONFORMED NAME: Biodel Inc DATE OF NAME CHANGE: 20050331 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McKinnon Alastair CENTRAL INDEX KEY: 0001687301 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33451 FILM NUMBER: 161979639 MAIL ADDRESS: STREET 1: C/O ALBIREO PHARMA, INC. STREET 2: 50 MILK STREET, 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02109 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2016-11-03 0 0001322505 ALBIREO PHARMA, INC. ALBO 0001687301 McKinnon Alastair C/O PHASE4 PARTNERS LIMITED 50 LOTHIAN ROAD, FESTIVAL SQUARE EDINBURGH X0 EH3 9WJ UNITED KINGDOM 0 0 1 0 Common Stock 1165447 I Held by Phase4 Ventures III GP LP Represents shares of common stock of Albireo Pharma, Inc. (the "Issuer"), formerly known as Biodel Inc., issued in the share exchange transaction that was completed on November 3, 2016 pursuant to an Amended and Restated Share Exchange Agreement, dated as of July 13, 2016, by and among Biodel Inc., Albireo Limited ("Albireo") and the holders of Albireo shares and notes convertible into Albireo shares. Consists of shares held by Phase4 Ventures III GP LP ("Phase4 GPLP") in its capacity as general partner of Phase4 Ventures III LP ("Phase4 III"). Phase4 GPLP is the general partner of Phase4 III. The general partner of Phase4 GPLP is Phase4 Ventures III General Partner Limited ("Phase4 GP"). Phase4 GP has appointed Phase4 Partners Limited ("Phase4 Partners") to act as the manager of Phase4 III. Dr. Alastair McKinnon, Denise Scots-Knight, Ph.D. and Charles Sermon are Directors of Phase4 Partners. Dr. Alastair McKinnon may be deemed to beneficially own the shares held by Phase4 GPLP in its capacity as general partner of Phase4 III, but disclaims beneficial ownership except to the extent of his pecuniary interest therein, if any. Exhibit 24.1 - Power of Attorney /s/ Peter A. Zorn, Attorney-in-fact 2016-11-07 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

Exhibit 24.1
POWER OF ATTORNEY


       Know all by these presents, that the undersigned hereby constitutes and
appoints Thomas A. Shea and Peter A. Zorn, each of Albireo Pharma, Inc. (the
"Company"), and Megan Gates, John Condon, Mark Higgins and Allyson Wilkinson,
each of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., signing singly,
with full power of substitution, the undersigned's true and lawful
attorney-in-fact to:
	(1)	execute for and on behalf of the undersigned, forms and authentication
documents for EDGAR Filing Access;

(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such forms and
authentication documents;

(3) 	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer, director and/or 10% stockholder of the Company, Forms 3, 4 and 5
in accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder;

	(4)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4 or 5
and timely file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority; and

	(5)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact, on behalf of
the undersigned pursuant to this Power of Attorney, shall be in such form and
shall contain such terms and conditions as such attorney-in-fact may approve in
such attorney-in-fact's discretion.

	The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, is not assuming, nor
is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934.

	This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed this 7th day of October, 2016.




By: /s/ Alastair McKinnon
Name: Alastair McKinnon